Five things for pharma marketers to know: Friday, November 21

Five things for pharma marketers to know: Friday, November 21

EMA revises its conflict of interest policy; AbbVie all-oral HCV combo drug receives positive EU recommendation; Merck may help NewLink Genetics scale production of its Ebola vaccine.

Sanofi offers glimpse of next-gen. insulin strategy

Sanofi offers glimpse of next-gen. insulin strategy

In a company-hosted seminar today, the Paris-based drugmaker gave investors a preview of the future of its diabetes franchise.

World projected to spend $1T on drugs in 2018

World projected to spend $1T on drugs in 2018

The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.

Five things for pharma marketers to know: Thursday, November 20

Five things for pharma marketers to know: Thursday, November 20

CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.

Unsealed court documents shed light on opioid marketing

Drug makers favor big spending on speakers' events and doctor outreach.

Gilead buys priority voucher for $125M

The scoop means the maker of HCV drugs Harvoni and Sovaldi can give any drug an accelerated review time.

Five things for pharma marketers to know: Wednesday, November 19

Five things for pharma marketers to know: Wednesday, November 19

Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.

Analyses support Pradaxa safety profile

Analyses support Pradaxa safety profile

Results of two post-market studies, conducted in part by Boehringer Ingelheim, corroborate the billion-dollar blood thinner's benefit/risk profile.

Tufts: drug dev costs have jumped 145%

Tufts: drug dev costs have jumped 145%

Researchers say the average cost of bringing a drug from concept to approval, and through post-approval assessments for reasons such as new doses or formulations, hovers at around $2.8 billion per drug in 2013 dollars.

PCSK9s stalk Merck's Vytorin

PCSK9s stalk Merck's Vytorin

A head-to-head comparison between Sanofi and Regeneron's experimental PCSK9 shows alirocumab lowers LDL levels more effectively than Merck's Zetia, which is part of the just-acquitted Vytorin.

Study finds new benefits in highly promising heart drug

A pipeline drug from Novartis has the potential to alter the progression of heart disease and keep patients out of the hospital.

Five things for pharma marketers to know: Tuesday, November 18

Five things for pharma marketers to know: Tuesday, November 18

Ackman walks away with $2.5 billion, despite no Allergan deal; Ranbaxy sues FDA over generic Nexium rights; Indian government's Health Ministry recommends breaking BMS cancer drug patent.

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Patients taking Vytorin experienced a 6.4% reduced relative risk for cardiovascular events, the company said.

Inovio sticks with prostate cancer drug

The Pennsylvania company says it will continue to develop its IO treatment, even without Roche's support.

Five things for pharma marketers to know: Monday, November 17

Five things for pharma marketers to know: Monday, November 17

Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.

Five things for pharma marketers to know: Friday, November 14

Five things for pharma marketers to know: Friday, November 14

Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.

HBA launches new look and programming

HBA launches new look and programming

The Healthcare Women's Business Association's new look comes with a side of new programming in an effort to reach more women in more places.

Valeant wins over docs with trips, fees

Valeant's war for Allergan also includes a soft touch when it comes to doctors: the WSJ reports that the company is winning over professionals with trips and consulting offers.

2015 an "important year" for Pfizer's IO pipeline, analysts say

A 4-1BB agonist highlights a discussion with analysts on the drug giant's immunoncology pipeline, with a number of combination options to be tested next year.

Five things for pharma marketers to know: Thursday, November 13

Five things for pharma marketers to know: Thursday, November 13

Actavis and Allergan are close to a deal in the $60-billionish range; AstraZeneca is working on a Brilinta antidote; scientists find what amounts to a naturally occurring version of Merck's Zetia.

Researchers: Pharmacy deserts contribute to access issues

Researchers: Pharmacy deserts contribute to access issues

Researchers studying the distribution of brick-and-mortar pharmacies in Chicago link adherence issues with geographic barriers to care.

Coalition urges gender-specific heart research

Coalition urges gender-specific heart research

The industry-supported group WomenHeart launched a heart failure awareness campaign Wednesday, as well as a push for gender-specific research.

Servier bets on match-stick-sized drug pump for diabetes drug

In a $1 billion deal, Servier will develop and market Intarcia Therapeutics' implantable device in markets outside the US and Japan.

Obesity drug war may be about more than marketing to the overweight

Obesity drug war may be about more than marketing to the overweight

Category news shows that marketing to the obese may mean marketing to related conditions.

Heart study results may be positive, but Vytorin boost unlikely

Heart study results may be positive, but Vytorin boost unlikely

An SEC filing by Merck suggests results of long awaited trial are favorable but come too late to have a commercial impact on sales of Vytorin and Zetia.

Merck HCV regimen only partially successful

Merck HCV regimen only partially successful

A Merck hep. C regimen that included two of its own agents paired with Gilead's Sovaldi faltered in four- and six-week regimens, according to analysts, leading to questions about the drugmaker's HCV prospects

Pradaxa antidote enters Phase III

Testing has already started abroad, and Boehringer says this is the first clinical trial that tests an antidote among patients taking a new oral anticoagulant.

Cigna lowers price of some HIV medications

The deal will cap the monthly price some patients may pay for medications such as Atripla.

Healthcare.gov reboot has new features

Patients will now be able to compare plans and identify ones that have disease-specific programs.

Five things for pharma marketers to know: Monday, November 10

Five things for pharma marketers to know: Monday, November 10

Dendreon goes Chapter 11; Mylan and Disney agree to EpiPen promotions; FDA pulls Ranbaxy generic claims for Nexium and Valcyte.

Five things for pharma marketers to know: Friday, November 7

Five things for pharma marketers to know: Friday, November 7

Woodcock says opioids without abuse-deterrent features are here to stay; UCB sells generic drug business to Advent and Avista; new antibiotic-free drug eradicates MRSA.

AstraZeneca Q3 sales rise, expects harsh 2015

AstraZeneca Q3 sales rise, expects harsh 2015

The company raised guidance for the end of the year and said Ranbaxy's being bounced from the Nexium competition probably means it has esomeprazole market to itself through 2014.

Ebola patient who used bio-filtration device reportedly free of virus

A medical device from Aethlon, used on an Ebola patient with multiple organ failure, was associated with promising results.

Five things for pharma marketers to know: Thursday, November 6

Five things for pharma marketers to know: Thursday, November 6

Eli Lilly's Cyramza approved for stomach and esophageal cancer; hedge fund may sue AbbVie for failed Shire acquisition; J&J's Olysio approved for use with Sovaldi.

CDC says cervical screening rates set to miss target

CDC says cervical screening rates set to miss target

The Centers for Disease Control and Prevention says 11.4% of women are still not screened for cervical cancer.

Microbiome linked to obesity

Researchers find that jet lag has an impact on the microscopic level.

Five things for pharma marketers to know: Wednesday, November 5

Five things for pharma marketers to know: Wednesday, November 5

The Hill outlines its healthcare expectations with a GOP Congress, Sanofi's executive shakeup may have an impact on MannKind's Afrezza launch, AstraZeneca's olaparib may have prostate cancer prospects, the FDA granted orphan status to an experimental Merrimack pancreatic cancer drug, and researchers are struggling to get Ebola virus samples.

HCB Health lands Alcon AOR

The Austin agency says it beat out FCB, Ogilvy CommonHealth, GSW Worldwide and H4B Chelsea for the work.

FDA adds language to GERD drugs

The new language is in response to a 2011 citizen's petition.

Study shows challenge of CNS drug approvals

For example: Tufts Center for the Study of Drug Development reseachers say it takes 18% longer to develop CNS drugs than it does non-CNS drugs.

Five things for pharma marketers to know: Tuesday, November 4

Five things for pharma marketers to know: Tuesday, November 4

AstraZeneca, Pharmacyclics and Janssen collab on Imbruvica; BMS to test HCV prices; WHO director general takes aim at pharma over lack of Ebola treatments.

Demand for obesity drugs creeps upwards

Demand for obesity drugs creeps upwards

Although sales have not skyrocketed, Arena and PBM Express Scripts have seen demand for prescription weight-loss medications rise, and researchers at The Obesity Society find the majority of weight-loss intervention candidates are eligible for prescription weight-loss medications.

Five things for pharma marketers to know: Friday, October 31

Five things for pharma marketers to know: Friday, October 31

Bristol-Myers Squibb's Opdivo improves survival rate in lung cancer patients; Businessweek says new Viagra spot targets a younger audience; NIH launches database to keep track of different countries' clinical trial regulations

Five things for pharma marketers to know: Thursday, October 30

Five things for pharma marketers to know: Thursday, October 30

Sanofi courts AstraZeneca CEO Soriot; Teva CEO optimistic on Copaxone patent ruling; AstraZeneca scores approval of diabetes combo drug.

Forbes's Matthew Herper sounds off on Viehbacher firing

Herper writes that Sanofi—without Viehbacher—is at risk of moving too slowly in an increasingly competitive industry.

Five things for pharma marketers to know: Wednesday, October 29

Five things for pharma marketers to know: Wednesday, October 29

Sanofi CEO fired; Sovaldi sales slow; Ranbaxy CEO affirms generic Nexium rights.

Pfizer undeterred from tax inversion deals

Despite the Treasury's crackdown on inversions, CEO Ian Read says they would still invert for the right deal.

Amgen has no plans to split up, layoffs continue

The drugmaker plans to cut 600-1,100 jobs next year.

Diabetes competition muddles Sanofi's future, despite strong sales

Diabetes competition muddles Sanofi's future, despite strong sales

Sanofi is expected to slash prices of its diabetes products to retain US market access.

A generic Nexium, at long last?

A generic Nexium, at long last?

With Ranbaxy's failure to launch a low-cost version of the acid reflux drug, pressure is mounting on FDA to speed a generic to market.

Five things for pharma marketers to know: Tuesday, October 28

Five things for pharma marketers to know: Tuesday, October 28

Sanofi CEO says diabetes sales will slow in 2015; Takeda/Lilly Actos settlement slashed by 99%; study says Sovaldi is cost-effective for prisoners.

FDA request delays Sarepta's Duchenne drug

The drug is now expected to be filed by mid-2015, rather than by year's end.

Cancer darling can't save Merck, as sales slip for quarter

Cancer darling can't save Merck, as sales slip for quarter

The drugmaker's pharma sales fell by 4%, even as Merck's Keytruda cancer darling received another Breakthrough Therapy designation.

Five things for pharma marketers to know: Monday, October 27

Five things for pharma marketers to know: Monday, October 27

Study shows Xarelto.com is top branded website among PCPs; Janssen launches IBD educational campaign; Merck's Keytruda scores Breakthrough Therapy designation in lung cancer.

Five things for pharma marketers to know: Friday, October 24

Five things for pharma marketers to know: Friday, October 24

Ebola comes to NY; AstraZeneca drops antibiotics; FDA approves hemophilia A drug.

Lilly sales fall, drugmaker to keep rep count low

Lilly sales fall, drugmaker to keep rep count low

Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.

Claims show BMS's Abilify remains strong

The antipsychotic's hold on the market has been steady, despite generics of drugs such as AstraZeneca's Seroquel.

App may diagnose glaucoma

Researchers say the iPad app could help assess vision loss.

Five things for pharma marketers to know: Thursday, October 23

Five things for pharma marketers to know: Thursday, October 23

FDA panel endorses Novartis psoriasis drug; court rules with Pfizer on cancer drug patent; drugmakers may look for indemnity against losses from Ebola vaccines.

Biogen's strong quarter eclipsed by patient death

Biogen's strong quarter eclipsed by patient death

Despite strong performance by its MS therapies, the drugmaker's robust third-quarter sales were overshadowed by the death of a patient taking Tecfidera.The patient had a rare brain infection.

GSK restructures, as respiratory disappoints

GSK restructures, as respiratory disappoints

GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.

NIH tests second Ebola vax in humans

Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.

Actavis, Sanofi reportedly spar for Omega

Bloomberg reports that the race to merge with Omega also includes privately-held Boehringer Ingelheim and Perrigo.

Senate hearing may be on horizon for HCV drug prices

Sen. Bernard Sanders (I-VT) could hold a hearing after midterm elections to discuss the impact of costly new HCV treatments on the US Department of Veterans' Affairs.

Study hints at how brands should reach Millennials

Study hints at how brands should reach Millennials

The Post X-er, Post-Boomer generation considers traditional healthcare "sick care."

Five things for pharma marketers to know: Tuesday, October 21

Five things for pharma marketers to know: Tuesday, October 21

Shire bows out of AbbVie acquisition; CVS's PBM will charge premium for consumers who fill scripts at tobacco-selling pharmacies; Reckitt Beckinser will rebrand following demerger.

Crohn's drug shows promise in mid-stage trial

Crohn's drug shows promise in mid-stage trial

Preliminary Phase-II data suggest remission rates among patients taking the drug were significantly better than those for subjects on current treatments.

Takeda's Contrave hits pharmacy shelves

Takeda's Contrave hits pharmacy shelves

Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.

Valeant-Allergan duel continues

Valeant indicated in its third-quarter earnings call that it expects to increase its bid for Allergan.

Five things for pharma marketers to know: Friday, October 17

Five things for pharma marketers to know: Friday, October 17

Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

AbbVie-free Shire could open new opportunities

AbbVie-free Shire could open new opportunities

AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.

Panel seems to like Novartis drug

Pre-review documents indicate a favorable opinion of the IL-17 inhibitor secukinumab.

New FDA division launches Jan. 1

Resignations stymied the Office of Pharmaceutical Quality's beginning.

Five things for pharma marketers to know: Thursday, October 16

Five things for pharma marketers to know: Thursday, October 16

AbbVie board recommends against Shire deal; consultancy says Netherland's generic bias hampers branded drug sales; Genentech and BI score FDA approval for fatal lung disease.

AbbVie reconsiders Shire

AbbVie reconsiders Shire

AbbVie is thinking about modifying or walking away from its offer to buy Dublin's Shire. A breakup would cost the Illinois company over $1.6 billion.

J&J offers government payer hep. C guarantee

The drugmaker is offering Scotland's NHS a money-back guarantee for Olysio patients.

New exclusivity rules confound

A draft guidance publication date determines whether drugmakers get three or five years of market exclusivity.

Cosmo moves to Ireland

Jilted Salix acquisition target Cosmo Pharmaceutical is headed for the Emerald Isle.

Five things for pharma marketers to know: Wednesday, October 15

Five things for pharma marketers to know: Wednesday, October 15

AbbVie's board to reconsider Shire move; docs warm up to ACA; Eisai orphan thyroid cancer drug receives Priority Review.

Hep. C medication boosts J&J earnings

Hep. C medication boosts J&J earnings

Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.

Pfizer gets palbo review date

Pfizer gets palbo review date

The FDA will vote for or against the breast cancer drug by April 13, 2015.

Harvoni's price is shaping the field

The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.

New Ireland tax rule does not fluster pharma

Ireland plans on closing off a tax advantage but pharma does not appear to flinch.

Five things for pharma marketers to know: Tuesday, October 14

Five things for pharma marketers to know: Tuesday, October 14

BMS, Janssen and Pharmacyclics to test Opdivo/Imbruvica pairing; Google's latest health experiment will connect docs and patients over video-conferencing Hangouts tool; Five Ranbaxy execs resign after generics firm was acquired by Sun.

FDA approves Sovaldi HCV combo

FDA approves Sovaldi HCV combo

The sofosbuvir-ledipasvir combo is expected to run the average genotype 1 patient $80,000.

Specialty prescription costs hurt across the board

Specialty prescription costs hurt across the board

Solutions for how to handle specialty medication costs are lacking, but the data around them shows a need for serious problem-solving.

Shire delays ADD medication submission

The company is working with the FDA on new clinical trial requirements.

Five things for pharma marketers to know: Thursday, October 9

Five things for pharma marketers to know: Thursday, October 9

Endo to acquire Auxilium for an estimated $2.6bn; Novartis says good-bye to three execs; NIH opens wallet for rare disease research; CMS's Open Payments show financial disparity between men and women; Clarient and GSK collaborate in cancer testing.

Amgen releases Humira biosimilar data

The company says ABP 510 hit its primary endpoint in an adalimumab comparison.

Researchers link prescriptions and time of day

In short: more antibotic prescriptions are written in the afternoon than in the morning.

Task Force endorses T2D screening

The US Preventive Services Task Force wants adults at risk for type 2 diabetes to get tested.

Cardiology groups endorse AZ's Brilinta over Plavix

Two cardiology associations advise prescribing Brilinta over Plavix for management of acute chest pain without electrocardiogram changes.

Teva narrows focus, trims R&D

Teva narrows focus, trims R&D

The drugmaker is poised to cut 14 pipeline projects loose.

Nearly half of consumers wary of healthcare costs, insurer finds

Nearly half of consumers wary of healthcare costs, insurer finds

Cigna said found paying for medications and hospitalizations were top healthcare concerns.

Hospital backlash begins after Genentech imposes change

Genentech's decision to pare access to three breast cancer drugs has spurred hospitals to take action.

Analysts see potential in Novartis's serelaxin

Analysts see potential in Novartis's serelaxin

Two regulatory agencies have rejected the drug, but analysts indicate the pipeline acute heart failure treatment could have limited market success.

Becton Dickinson buys CareFusion

An analyst says the $12.2B deal creates a one-stop shopping experience for hospitals.

Five things for pharma marketers to know: Monday, October 6

Five things for pharma marketers to know: Monday, October 6

Novartis BMS collaboration to evaluate Opdivo paired with three lung cancer treatments; Forbes weighs in on 60 Minutes segment; Sanofi management disagreements delay established drug portfolio sale; FDA sets price for Rare Pediatric Disease Priority Review vouchers; the GPhA challenges lawmakers' misconceptions of generic drug prices.

Five things for pharma marketers to know: Friday, October 3

Five things for pharma marketers to know: Friday, October 3

Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep

Lilly drops lupus drug from trials

Lilly drops lupus drug from trials

Eli Lilly said it discontinued tabalumab, a drug being tested in Phase-III trials for lupus, after it failed to outperform the standard of care.

Email Newsletters

MM&M inVISION